Neo Ivy Capital Management’s Integra LifeSciences IART Stock Holding History

Neo Ivy Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-320	Closed	-$12K	–	363
2023 Q3	$12K	Buy	+320	New	+$13.5K	0.01%	296
2022 Q4	–	Sell	-716	Closed	-$30K	–	435
2022 Q3	$30K	Buy	+716	New	+$36.7K	0.08%	266
2022 Q2	–	Sell	-3,720	Closed	-$240K	–	501
2022 Q1	$240K	Buy	+3,720	New	+$245K	0.22%	166
2021 Q4	–	Sell	-5,689	Closed	-$267K	–	517
2021 Q3	$267K	Buy	+5,689	New	+$402K	0.31%	119
2020 Q3	–	Sell	-5,689	Closed	-$267K	–	532
2020 Q2	$267K	Buy	5,689 +3,527	+163%	+$173K	0.31%	119
2020 Q1	$97K	Buy	+2,162	New	+$113K	0.16%	227

Other funds holding IART

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neo Ivy Capital Management's IART Position: Q4 2023 in Review

Neo Ivy Capital Management sold out of Integra LifeSciences (IART) in Q4 2023, closing a stake of 320 shares — an estimated $12K sold.

Neo Ivy Capital Management first reported a position in IART in Q1 2020 and held it in 6 quarters. The position peaked at $267K in Q3 2021. 284 funds tracked by Wall St. Rank hold IART as of Q4 2023.

Neo Ivy Capital Management reported no remaining Integra LifeSciences position as of Q4 2023 after selling out during the quarter.
Neo Ivy Capital Management sold 320 Integra LifeSciences shares in Q4 2023, an estimated $12K.
Neo Ivy Capital Management first reported a position in Integra LifeSciences in Q1 2020 and held it in 6 quarters.
Neo Ivy Capital Management's Integra LifeSciences position peaked at $267K in Q3 2021.
284 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2023.

Based on Neo Ivy Capital Management's 13F filing for Q4 2023, filed 26 Feb 2024.